Jing Liang 🇺🇦 Profile picture
Entrepreneur. Drug hunter. Novice biotech scripophile. Anti-ideologues. Proudly blocked by @VPrasadMDMPH. https://t.co/zMzJBoov2V
Nov 13 8 tweets 3 min read
1/ This is the MOST important insight from the $AMGN hidden tabs "leak".

I am surprised no sell-side analyst have picked up on this. cc' @DanielJDrucker

Amgen had hidden data from its AMG 598 w/ or without Liraglutide trial in the excel file.

clinicaltrials.gov/study/NCT03757…Image 2/

This trial is the foundation of AMG133. AMG 598 is the GIPR antibody alone without the GLP-1 conjugates.

Amgen tested AMG598 alone and AMG 598 + Liraglutide to see its efficacy in humans. AMG133's foundational preclinical publications used Liraglutide as well.
Nov 21, 2023 10 tweets 4 min read
1/ A short thread on AMG-133's Phase 2 trial.

Pure speculation on my part on why I think Amgen is testing AMG-133 as weekly as well as monthly injections.

AMG-133 had spectacular Phase 1 SAD MAD data. Still the best 12-week weight loss data to date.
Image
Image
2/
The Phase 1 SAD dosed up to 840mg, and the MAD tested 3 doses at up to 420mg. There was a nice dose response.

But it made me wonder, why did Amgen not push the dose above 420mg? Image
Oct 11, 2022 13 tweets 7 min read
1/ History of Bioartic:

Founded in 2003.
Initial investment made by Karolinska Innovation AB <-- really want to dig deeper into this fund/model.

karolinskainnovations.ki.se/en/

bioarctic.se/en/history-189… Image 2/ WOW I am blown away by these numbers.

From BioArctic 2017 prospectus:

Pre-IPO, The 2 founders owned 94.3% of the company! 14 years after founding!

Main investors were original Karlinska Institute, and Uppsala University Holdings AB.

bioarctic.se/en/wp-content/… Image
May 25, 2022 23 tweets 5 min read
1/ When I look at the biotech business model as an entrepreneur, I honestly feel lost.

A bit of history.

When $TRGT discontinued all clinical programs and reverse merged with $CBIO, its assets were sold off.

My company got 3 phase 2 molecules for $1m up front. 2/

I emptied my 401K and borrowed another $500K from 2 HNWI friends at high interest rate to pay for the upfront.

The deal terms were $1m upfront + milestones and royalties
May 24, 2022 32 tweets 5 min read
1/ As founder of a now liquidated VC-backed biotech, I really do think many public biotech companies trading under cash should liquidate 2/ My company Attenua liquidated its assets after our lead clinical program failed Phase 2a. Sure we could have used the remaining $$$ to go after other programs, but it required pre-clinical studies, and time to clinic would likely be too long.
Nov 18, 2021 15 tweets 3 min read
1/

Nudged by @eperlste, I'd like to share my own rules of the Biotech Game.

This is NOT a complete playbook of biotech - this game is so complex that there is no single playbook. But if you are looking for one, start w/ @PeterKolchinsky's book:

2/
My own "rules" is a decision-making framework that I use to determine the sequencing of activities when starting a biotech.
Nov 18, 2021 4 tweets 1 min read
1/ There is so much discussion on Twitter regarding Founder-led vs VC-led (or VC assembled team).

I feel the emphasis is misplaced. There is no right model.

In some instances, i.e., new platform tech, founder-led may be better. A new MOA small molecule, VC-led may be better 2/ I think the discussion should focus around:

- Maximize economics for academic inventors
- Maximize probability of commercialization
- How to recruit the best team
- Retaining reasonable degree of control over direction of company

Whether or not founder is CEO is secondary
Jul 11, 2021 4 tweets 2 min read
1/ Lets compare breakthrough infection rates of fully vaccinated healthcare workers in US (receiving Pfizer/Moderna) vs those in Thailand (Sinovac) 2/

Story from Reuters:

Of 677,348 healthcare workers fully vaccinated with Sinovac, 618 became infected with coronavirus

reuters.com/world/asia-pac…
Jul 11, 2021 5 tweets 2 min read
I will take the other side of this bet. It has not happened and not from the lack of trying.

insideevs.com/news/485298/gl… This is the reason why @AlbertBridgeCap's reason is too simplistic.

No OEM has managed to design a EV experience better than Tesla.

Therefore, every OEM will be faced with huge losses if it attempts to "sell more" cars than Tesla.

Dec 5, 2020 11 tweets 4 min read
So Bothell was not "fine" as many assumed.

Observations:

1/ 68K sq ft facility took 10 days to inspect (10/7-16). Lonza plant is 300k sq ft. A brand new plant, with much more complex manufacturing of viral vectors.

If I were to estimate, it will take 14 days to inspect. 2/ Item 1 on 483: Looks like batch failures were not properly investigated. Looks like an inadequate Quality System to me.
Mar 20, 2020 12 tweets 4 min read
1/ Rant coming

I hate journalism that wants to tell a sexy story, and in doing so, selectively ignores facts.

It is the case here with @jetjocko's reporting of chloroquine.

The chloroquine/hydroxychloroquine hypothesis did not start with the French study! 2/ The idea of it came from off-label use by frontline doctors in China and Korea.

The scientific rationale came from post-SARS research in 2004 by Belgian researchers

ncbi.nlm.nih.gov/pubmed/15351731 Image
Feb 9, 2020 11 tweets 5 min read
People, please stop spreading conspiracy theories. Some of you should be smarter than this.

Let me debunk this conspiracy theory floating around suggesting spike in SO2 emissions in Wuhan is due to massive burning of bodies

1/ 2/ According to this 2018 Green Peace report on global SO2 emissions, annual SO2 emissions from Wuhan is:

85 Kilotons per year

greenpeace.org.au/wp/wp-content/…